{"id":"NCT01072630","sponsor":"Cephalon","briefTitle":"Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder","officialTitle":"A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-03","primaryCompletion":"2012-11","completion":"2012-11","firstPosted":"2010-02-22","resultsPosted":"2015-01-26","lastUpdate":"2016-04-27"},"enrollment":492,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Depression"],"interventions":[{"type":"DRUG","name":"Armodafinil","otherNames":["Nuvigil","CEP-10953"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Armodafinil 150 mg/day","type":"EXPERIMENTAL"},{"label":"Armodafinil 200 mg/day","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study is to determine whether armodafinil treatment, at a dosage of 150 mg/day, is more effective than placebo treatment as adjunctive therapy to mood stabilizers for treatment of adults with major depression associated with bipolar I disorder.","primaryOutcome":{"measure":"Change From Baseline to Week 8 in the Total Score From the 30-Item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)","timeFrame":"Day 0 (baseline), Week 8","effectByArm":[{"arm":"Placebo","deltaMin":-18.8,"sd":1.02},{"arm":"Armodafinil 150 mg/Day","deltaMin":-20.9,"sd":1.02},{"arm":"All Armodafinil","deltaMin":-20.7,"sd":0.98}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1302"},{"comp":"OG000 vs OG002","p":"0.1350"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":11},"locations":{"siteCount":92,"countries":["United States","Argentina","Australia","Bulgaria","Canada","France","Poland","South Africa","Spain","Ukraine"]},"refs":{"pmids":["25933099"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":231},"commonTop":["Headache","Diarrhoea","Nausea","Insomnia","Dry mouth"]}}